Haleon
Haleon is a health company that brings together deep human understanding and trusted science.
Launch date
Employees
Market cap
€41.8b
Enterprise valuation
€51.7b (Public information from Sep 2024)
Share price
$10.46 HLN
Company register number 13691224
Weybridge England (HQ)
Financials
Estimates*
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 9.9b | 9.5b | 10.9b | 11.3b | 11.4b | 11.7b | 12.3b |
| % growth | 17 % | (4 %) | 14 % | 4 % | 1 % | 3 % | 4 % |
| EBITDA | 1.9b | 2.0b | 2.2b | 2.3b | 2.9b | 3.0b | 3.2b |
| % EBITDA margin | 19 % | 20 % | 20 % | 21 % | 25 % | 26 % | 26 % |
| Profit | 1.1b | 1.4b | 1.1b | 1.0b | 1.5b | 1.7b | 1.9b |
| % profit margin | 12 % | 15 % | 10 % | 9 % | 13 % | 14 % | 15 % |
| EV / revenue | - | - | 3.7x | 3.4x | 3.7x | 3.5x | 3.3x |
| EV / EBITDA | - | - | 18.5x | 16.3x | 14.7x | 13.9x | 12.9x |
| R&D budget | 304m | 257m | 300m | 311m | - | - | - |
| R&D % of revenue | 3 % | 3 % | 3 % | 3 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
N/A | Corporate spinout | ||
* | N/A | £804m | Secondary |
* | N/A | N/A | Post IPO Debt |
| Total Funding | - | ||
